204 related articles for article (PubMed ID: 36723792)
1. Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus.
Kim J; Lim TY; Park J; Jang YS
J Microbiol; 2023 Jan; 61(1):131-143. PubMed ID: 36723792
[TBL] [Abstract][Full Text] [Related]
2. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
3. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
[TBL] [Abstract][Full Text] [Related]
8. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
10. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
11. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
12. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
[TBL] [Abstract][Full Text] [Related]
13. Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.
Rajpoot RK; Shukla R; Arora U; Swaminathan S; Khanna N
Sci Rep; 2018 Jun; 8(1):8643. PubMed ID: 29872153
[TBL] [Abstract][Full Text] [Related]
14. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
[TBL] [Abstract][Full Text] [Related]
15. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
16. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
[TBL] [Abstract][Full Text] [Related]
17. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
Front Immunol; 2019; 10():59. PubMed ID: 30761131
[TBL] [Abstract][Full Text] [Related]
18. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
20. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]